Falk Symposium 200

Therapeutic Strategies in Diseases of the Digestive Tract – 2015 and Beyond

October 16 – 17, 2015
Konzerthaus Freiburg
Freiburg, Germany

Program

General Information:
FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany
Congress Department
Telephone: +49(0)761/1514-0
Telefax: +49(0)761/1514-359
E-Mail: symposia@falkfoundation.de
www.falkfoundation.org
Preface ............................................................. 4
Scientific Program ............................................. 6
Hans Popper Award ........................................... 9
Posters ............................................................ 11
List of Speakers, Moderators and Scientific Organizers ........................................... 20
Information ........................................................ 24

9 credit hours (CME) have been awarded for the Falk Symposium 200 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

The last decades have brought an abundance of new knowledge regarding pathophysiology and practical advances in gastroenterology and hepatology. Most recently the development of almost perfect drugs to cure chronic hepatitis C is a good example as is the advent of several new options for the treatment of inflammatory bowel diseases. However, many unmet needs remain, for example effective therapies for carcinoma of pancreas, liver and stomach or the reversal of liver fibrosis.

The Falk Foundation has supported the advancement of understanding of pathophysiology, diagnosis and treatment of disorders of the digestive tract for meanwhile 48 years in particular by providing the possibility of scientific communication during the Falk Symposia. This symposium “Therapeutic strategies in diseases of the digestive tract – 2015 and beyond” will be symposium 200 in this series and can be considered a milestone. For this reason it is not devoted to a single disease entity or organ but to the state of the art and a look into the future of digestive diseases overall. The scientific organizers have attempted to cover the most important problems and developments and to provide an excellent faculty to present these in 26 lectures. They will describe the current state and try to predict further advances based on new insights into causes and mechanisms.

We hope that participants will gain new insights and connect with experts and colleagues and we all together will enjoy a journey through our innovative discipline.

Marco J. Bruno  Emad M. El-Omar  Pere Ginès  Daniel K. Podolsky  Jürgen Schölmerich
Therapeutic Strategies in Diseases of the Digestive Tract – 2015 and Beyond

October 16 – 17, 2015
Konzerthaus Freiburg
Freiburg, Germany

Registration:
Thursday, October 15, 2015
8.30 – 18.00 h
at the congress office

Scientific Organization:
M. J. Bruno, Rotterdam (The Netherlands)
E. M. El-Omar, Aberdeen (Scotland)
P. Ginès, Barcelona (Spain)
D. K. Podolsky, Dallas (USA)
J. Schölmerich, Frankfurt (Germany)

Congress Venue:
Konzerthaus Freiburg
Konrad-Adenauer-Platz 1
79098 Freiburg
Germany

Information:
Prof. Dr. Jürgen Schölmerich
Universitätsklinikum Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt
Germany
Telephone: +49 (0)69/6301-7040
Telefax: +49 (0)69/6301-83076
E-Mail: aed@kgu.de

Official Language:
English.
Simultaneous translation into German.

Posters:
For details see page 11
Friday, October 16, 2015

8.30 Welcome and Introduction

J. Schölmerich, Frankfurt

Session I
Esophagus

Chair: C. Ell, Offenbach; T. Matysiak-Budnik, Nantes

8.40 Eosinophilic esophagitis: Not just for children
A. Schoepfer, Lausanne

9.00 Endoscopic management of early cancer
R. E. Pouw, Amsterdam

9.20 Achalasia: From bench to POEMs
G. E. Boeckxstaens, Leuven

9.40 State-of-the-Art Lecture:
From reflux to cancer
R. F. Souza, Dallas

10.10 Coffee break with poster session

Session II
Stomach

Chair: E. M. El-Omar, Aberdeen; P. Malfertheiner, Magdeburg

10.40 Functional dyspepsia and gastroparesis
M. Camilleri, Rochester

11.00 Strategies for prevention of gastric cancer:
Progress from mass eradication trials
K. Sugano, Tochigi

11.20 Failed eradication of Helicobacter pylori:
What should be done?
F. Mégraud, Bordeaux

11.40 State-of-the-Art Lecture:
New biology to new treatment of gastric cancer
R. Peek, Nashville

12.10 Lunch break with poster session

13.10 Presentation of the Hans Popper Award
M. P. Manns, Hannover

13.20 Hans Popper Award Lecture:
Cholestatic and autoimmune liver disease -
From genetics to environment and back
T. H. Karlsen, Oslo
Saturday, October 17, 2015

Session III
Pancreas

Chair: M. J. Bruno, Rotterdam; T. Gress, Marburg

8.30 Decision making in necrotizing pancreatitis  M. W. Büchler, Heidelberg
8.50 Development of pancreatic cancer: Targets for early detection and treatment  M. M. Lerch, Greifswald
9.10 Autoimmune pancreatitis: A riddle wrapped in an enigma  G. Webster, London
9.30 State-of-the-Art Lecture: Improving the outcome of acute pancreatitis: Current guidelines and beyond  M. J. Bruno, Rotterdam

10.00 Coffee break with poster session

Session IV
Systemic disorders and systemic approaches in the digestive tract

Chair: A. Dignass, Frankfurt; Y. Liu, Beijing

10.30 Gut and liver in vasculitic disorders  U. Müller-Ladner, Bad Nauheim
10.50 Gut and liver in sepsis  C. Trautwein, Aachen
11.10 Five genetic disorders a gastroenterologist should know  J. Cho, New York
11.30 Molecular imaging as a basis of treatment  R. Atreya, Erlangen
11.50 State-of-the-Art Lecture: Microbiota as therapeutic targets  R. J. Xavier, Boston
12.20 Presentation of Poster Prizes  P. Ginès, Barcelona
12.30 Lunch break with poster session
Saturday, October 17, 2015

Session V
Small and large bowel

Chair: D. K. Podolsky, Dallas; G. Rogler, Zurich

13.30 IBS: More than motility
13.50 Therapeutic approaches in IBD beyond the immunosuppressive paradigm
14.10 Targeted therapies in colon cancer today and tomorrow
14.30 Endoscopy beyond visible light as basis of treatment
14.50 State-of-the-Art Lecture:
Building a better human intestine
15.20 Coffee break with poster session

Session VI
Liver and biliary system

Chair: J. Schölmerich, Frankfurt; S. Zeuzem, Frankfurt

15.50 FXR agonists for liver disease
16.10 Treatment of liver fibrosis
16.30 Treatment of hepatocellular carcinoma
16.50 State-of-the-Art Lecture:
Hepatology after hepatitis C
17.20 Conclusion and farewell
Hans Popper (1903-1988)

Hans POPPER was born 1903 in Vienna where he received his primary and secondary education and started Medical School in 1922. As a student already he was engaged in research in biochemistry, then a quite virgin discipline. Some of his student publications are still quoted today. After graduation in 1928 he continued in pathology and then, in 1933, moved to the famous Department of Internal Medicine at the University of Vienna where he acquired experience with emphasis on renal and hepatic diseases. A promising career was terminated in 1938 by the occupation of Austria. Hans POPPER escaped to the United States and received a research fellowship in Chicago at Cook County Hospital. He started de novo with his own work in the laboratory, had a private practice in gastroenterology, and acquired a Ph.D. in pathology and physiology at the University of Illinois. Within a few years he assembled a hepatic research group leading to the foundation of the Hektoen Institute for Medical Research with POPPER the first director. During World War II he served in the Army, and after return to civilian life, he became the director of pathology Cook County Hospital, Chicago. He did research on all aspects of liver disease and together with Fenton SCHAFFNER he wrote one of the first major English textbooks on the liver, published in 1957, followed by the continuing edition of „Progress in liver Diseases“. In the late forties he founded the American Association for the Study of the liver (AASLD); its first meeting taking place in the library of the Hektoen Institute. From these small beginnings grew the large AASLD of today. Subsequently, he organized with Dame Sheila SHERLOCK the International Association for the Study of the Liver (IASL), which in turn stimulated the creation of many continental and national societies. These, together with the many international symposia of the FALK Foundation, in which Hans POPPER played a leading role, contributed greatly to the establishment of hepatology as a discipline. Although the Chicago years were scientifically most rewarding, Hans POPPER accepted in 1956 the challenging offer to succeed Paul KLEMPERER as pathologist-in-chief at the highly prestigious Mount Sinai Hospital in New York to become professor at Columbia University in New York. Within a few years a new research group with scientists from all over the world assembled at Mount Sinai. Major fields of his scientific interests were cholestasis, the immunology of viral hepatitis, basic mechanisms of cellular and molecular pathology, including communication between liver cells, and hepatic carcinogenesis. The sophisticated research work performed at Mount Sinai Hospital led to the creation of Mount Sinai Medical School in 1964 with Hans POPPER the founding acting dean. For his Medical School he developed a unique philosophy searching for balance between quantitative molecular biology, attention to social and psychological needs of the patient, and the demands of the community at large. Hans POPPER combined the chairmanship of pathology, the leadership of the liver unit with the deanship of academic affairs until 1971, when he retired as chairman of the pathology department, but remained as Gustave L. Levy Distinguished Service Professor. After his retirement he became a Fogarty Scholar at the National Institutes of Health in Bethesda and began cooperations with several laboratories and universities, particularly in the field of viral hepatitis and liver carcinogenesis. He called himself a Traveller in Academic Affairs. With unrelenting enthusiasm and inexhaustible energy in this 8th decade he acquired competence in the modern technology of molecular and cellular biology. The hepatologic community greatly benefited from his inspiring scientific contributions (almost 800 publications and 23 books), and his critical judgement and stimulating discussions at meetings until a few weeks before his death on May 6, 1988 at the age of 85.
His merits have been honored by memberships in four major academies, including the National Academy of Sciences USA, 14 honorary doctorates, many medals and prizes, and honorary memberships or presidencies of national and international societies. Last but not least the laboratories at Mount Sinai School of Medicine, New York, and at the Department of Pathology of the University of Vienna are named after him. He has left us a rich heritage and we can only aspire to follow in his footsteps.

Leonardo Bianchi

International Hans Popper Award 2015

The International Hans Popper-Award was created by the Falk Foundation e.V. and will be presented for the eighth time on the occasion of the Falk Symposium 200 on October 16, 2015. The prize will be endowed with EUR 25,000,-. It is awarded for outstanding contributors to basic and experimental hepatology, including molecular genetics, molecular biology, physiology, biochemistry and pathology of acute and chronic liver diseases and its sequelae.

Members of the Prize Committee:

M. Colombo, Milan (Italy)
P. Ginès, Barcelona (Spain)
M. Houghton, San Francisco (USA)
M. Omata, Tokyo (Japan)
R. Perrillo, Dallas (USA)
M. Trauner, Vienna (Austria)

Hans Popper Award Winners 1989 - 2015:

1989 - H. C. Thomas, London (Great Britain)
1992 - M. Rizzetto, Turin (Italy)
1995 - M. P. Manns, Hannover (Germany)
1999 - M. Houghton, Emeryville (USA)
2003 - S. L. Friedman, New York (USA)
2006 - P. Ginès, Barcelona (Spain)
2012 - J. Bruix, Barcelona (Spain) / J. M. Llovet, Barcelona (Spain)
2015 - T. H. Karlsen, Oslo (Norway)

Coordinator of the Hans Popper Award Committee:

Prof. Dr. Michael P. Manns
Klinik für Gastroenterologie
Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Germany
Poster Session

Posters will be exhibited on October 16-17, 2015 in the Konzerthaus Freiburg. The authors will be in attendance during coffee and lunch breaks on both days.

1. Serotonin: A marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients?  
H.A. Abd el Moety, D.A. Maharem, S.H. Gomaa (Alexandria, EG)

2. Malnutrition prevalence among patients with liver cirrhosis in relation to the duration of cirrhosis history  
A. Adamenka (Minsk, BY)

3. Evaluation of the Lavandula stoechas L. extract in the experimental model of irritable bowel syndrome induced by acetic acid  

A. Alisa (London, GB)

5. Development and validation of a new disease severity index: The inflammatory bowel disease index (IBDex®)  
L. Alrubaiy, P. Dodds, H.A. Hutchings, I.T. Russell, A. Watkins, J.G. Williams (Swansea, GB)

6. The Crohn’s and ulcerative colitis questionnaire-12 (CUCQ-12): A short quality of life tool for inflammatory bowel disease  

7. Comparison of affective temperament profile between patients with irritable bowel syndrome and healthy controls  
K. Altinbas, E. Akbal, F. Günes (Canakkale, TR)

8. Two-week protein-enriched low-calorie diet (HEPAFAST) shows rapid improvement of fatty liver as assessed by controlled attenuation parameter  
A. Arslanow, M. Teutsch, H. Walle, F. Lammert, C.S. Stokes (Homburg, Kirkel, DE)

9. Primary colon involvement in non-Hodgkin lymphomas  
D. Badea, M. Badea, A.-M. Genunche-Dumitrescu, P. Mitrut, A. Badea (Craiova, RO)

10. Therapeutic approach in primary indolent gastrointestinal lymphoma  
M. Badea, D. Badea, A.-M. Genunche-Dumitrescu, P. Mitrut, A. Badea, D. Duta (Craiova, RO)

11. Loss of integrin β6 (ITGB6) protects from colon cancer development in vivo  
12. Loss of integrin β6 (ITGB6) results in aggravated acute and chronic DSS-induced colitis

13. Diagnosis and treatment management in digestive-cutaneous purpura in young patients
   M.C. Bezna, C. Deliu, M. Bezna, C. Pitis (Craiova, RO)

14. Mesalazine-induced thrombocytopenia and pericarditis in paediatric inflammatory bowel disease
   T. Bhaduri, B. Bhaduri (London, Maidstone, GB)

15. MiR-155 plays a central role in Th17 cell development and in the pathogenesis of intestinal inflammation
   T. Bormann, I. Backert, C. Neufert, M.F. Neurath, S.J. Wirtz, M.J. Waldner (Erlangen, DE)

16. Viral modulation of extrinsic cell death pathways

17. ERAP1 gene polymorphisms in Turkish patients with inflammatory bowel disease and ankylosing spondylitis

18. Treatment of dysbiosis in uncomplicated diverticular disease of the colon
   I. Copaci, M. Mihaila, G. Chiriac, L. Micu, G. Constantinescu (Bucharest, RO)

19. Extra-colonic cancer risk in collagenous colitis

20. Clinical-biological particularities of non-alcoholic fatty liver disease in Romanian patients
   D.N. Dascalu (Sibiu, RO)

21. Infliximab or adalimumab for Crohn's disease
   M. Dranga, C. Mihai, O. Gavriltescu, A.-M. Chiosa, A. Didita, M.A. Badea, C. Cijevschii Prelipcean (Iasi, RO)

22. Prevalence of celiac disease in patients with cystic hydatid disease: May they have been related to same environmental conditions?
   A.C. Dülger, H. Güdüküoğlu, Y.E. Beyhan, Z.T. Cengiz, M. Aydin, B. Suvak, B. Gültepe (Van, Istanbul, TR)

23. Intestinal anti-inflammatory effects of total alkaloids of Fumaria capreolata in the DNBS model of mice colitis
24. The antidepressant agomelatine reduces intestinal inflammation in DNBS experimental colitis in mice
   J. Garrido-Mesa, A. Rodriguez-Nogales, F. Algieri, T. Vezza, M.P. Utrilla,
   M.E. Rodriguez-Cabezas, J. Leon, J. Salmeron, J. Galvez (Granada, ES)

25. Pentoxifylline and prednisone versus prednisolone for severe alcoholic hepatitis
   O. Gavrilescu, C. Mihai, M. Dranga, A.-M. Chiosa, A. Didita, M.A. Badea,
   C. Cijevschi Prelipcean (Iasi, RO)

26. Medical history of eradicated Helicobacter pylori infection as an individual risk factor for gastric cancer
   A.-M. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea (Craiova, RO)

27. Sequential therapy for Helicobacter pylori eradication as a first-line treatment for patients with type 2 diabetes
   A.-M. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea (Craiova, RO)

28. Molecular profiling with determination of KRAS TP53 and KIT mutations with further clinical implications for adenocarcinomas of ventricular cardia of a mother and a daughter
   S. Gluszek, D. Koziel, A. Kowalik, S. Ziemba, S. Urbaniak-Wasik, A. Wincewicz,
   S. Sulkowski (Kielce, PL)

29. Metabolic syndrome and probiotics
   M. Gorenjak, D. Skorjanc, T. Langerholc, A. Zafosnik, V. Kalacun, P. Skok (Hoce, Maribor, SI)

30. Influence of the intestinal microbiota on expression of cell death regulators
   C. Günther, G. He, M. Hefele, B. Buchen, H. Neumann, M. Basic, A. Bleich,
   M. Blaut, A. Woting, M.F. Neurath, S. Wirtz, C. Becker (Erlangen, Hannover,
   Berlin, DE)

31. Decreased fibrogenesis upon pirfenidone in a newly developed mouse model of intestinal fibrosis
   M. Hausmann, R. Meier, C. Lutz, S. Fagagnini, G. Bollmann, A. Hünerwadel,
   C. Mamie, S. Lang, G. Rogler (Zurich, CH)

32. The role of epithelial caspase-8 during infection with Salmonella typhimurium
   M. Hefele, C. Günther, S. Wirtz, M. Mahapatro, M.F. Neurath, C. Becker
   (Erlangen, DE)

33. IgG4-related autoimmune pancreatitis, a mimicker of pancreatic cancer
   I. Hoffmanova, R. Gürlich, V. Janik, A. Szabo, Z. Vernerova (Prague, CZ)

34. Reduced volume regimen in colonoscopy using PEG-3350 (Endofalk®): Results of a randomised prospective study
   E. Ivanova, N. Anikina, D. Seleznev, E. Tikhomirova, E. Fedorov (Moscow, RU)

35. Expression of Collagen IV is associated with neoangiogenesis and lymph node metastases in pancreatic ductal carcinoma
   K. Jakubowska, A. Pryczynicz, J. Zinczuk, W. Famulski, A. Kemona, A. Niewinski,
   K. Guzinska-Ustymowicz (Bialystok, PL)
36. Celiac disease serology in naive rheumatoid arthritis patients
   P. Jeremias, T. Matthias, S. Reuter, A. Lerner, A. Schwarting (Wendelsheim, Mainz, DE; Haifa, IL)

37. Factors related to low serum vitamin B12 levels in older patients with non-atrophic gastritis in comparison to patients with normal vitamin B12 levels

38. Comparison of three different scoring systems for risk stratification in geriatric patients with acute upper gastrointestinal bleeding
   C. Kalkan, F. Karakaya, A. Tüzün, K. Karabiyik, I. Soykan (Ankara, TR)

39. A rare case of fulminant pseudomembranous colitis in elderly

40. Azathioprine-induced haemorrhagic gastritis
   P. Karatzas, E. Archavlis, S. Anastasiadis, I. Internos, K. Papamichael, X. Tzannotakou, G.J. Mantzaris (Athens, GR)

41. The stressometer: A simple, valid and responsive measure of psychological stress in inflammatory bowel disease patients
   D. Keegan, K. Byrne, G. Cullen, G.A. Doherty, B. Dooley, H.E. Mulcahy (Dublin, IE)

42. Hypovitaminosis D: A harbinger of biochemical non-response in primary biliary cirrhosis
   C. Kittler, S. Stengel, P.J. Trivedi, A. Stallmach, T. Bruns (Jena, DE; Birmingham, GB)

43. Steroid-refractory or complicated Crohn’s disease? Is the diagnosis right?
   Z. Koncz, M. Horvath, P. Sahin (Budapest, HU)

44. Concentration of soluble selectins (sP-, sE-, sL-) in colorectal cancer
   A. Korniluk, V. Dymicka-Piekarska (Bialystok, PL)

45. KID: A database of capsule endoscopy images and videos with paired annotations for developing automatic recognition software
   A. Koulaouzidis, D.K. Lakovidis (Edinburgh, GB; Lamia, GR)

46. Evaluation of prealbumin and retinol binding protein as severity markers during an episode of acute pancreatitis
   M. Kovacheva-Slavova, S. Siminkovitch, B. Vladimirov, J. Genov, R. Mitova, B. Golemanov, P. Gecov, J. Hristova (Sofia, BG)

47. Upper gastrointestinal cancer mortality trend in Albania
   F. Kraja, I. Akshija, B. Kraja, R. Bici, A. Sallaku (Tirana, AL)

48. Anti-neo-epitope tTg complexed to gliadin are more reliable than tTg for celiac disease diagnosis
   A. Lerner, P. Jeremias, S. Neidhöfer, T. Matthias (Haifa, IL; Wendelsheim, DE)

49. The annual incidence/prevalence of autoimmune diseases is increasing worldwide
   A. Lerner, P. Jeremias, T. Matthias (Haifa, IL; Wendelsheim, DE)
50. Immunomodulatory properties of antibiotics in DNBS-colitis: Micro-RNA expression and gut microbiota diversity

51. Vitamin D in cirrhotic patients with an infection
   E.G. Malaeva (Gomel, BY)

52. Regulation of colitis-associated cancer development via HIF1α activation in myeloid cells
   T. Marini-Menezes, S. Foersch, A. Jefremow, J. Gonzales Menezes, S. Wirtz, M.F. Neurath, M.J. Waldner (Erlangen, DE)

53. Inhibition of mitochondrial Lon protease induces an apoptosis in the primary hepatocellular carcinoma cells
   E.A. Martinova, E.V. Poddubskaya, T.V. Rotanova (Moscow, RU)

54. Effective ways to overcome the refractory gastroesophageal reflux disease
   G.S. Maslova, I.M. Skrypnyk, O.F. Gopko (Poltava, UA)

55. Industrial food additive microbial transglutaminase is immunogenic in children with celiac disease
   T. Matthias, P. Jeremias, S. Neidhöfer, A. Lerner (Wendelsheim, DE; Haifa, IL)

56. DNA methylation profiling in inflammatory bowel disease: New insights into disease pathogenesis and activity

57. Evaluation of the Lactobacillus fermentum in the DCA experimental model of irritable bowel syndrome: Impact on anxiety behavior

58. Low molecular weight dextran sulfate nanocapsules as inhibitors of Helicobacter pylori adhesion to gastric cells: An alternative therapy for Helicobacter pylori infection
   B. Menchicchi, E. Savvaidou, A. Hensel, F.M. Goycoolea (Erlangen, Münster, DE)

59. The modulation of tumor growth and inflammation by metformin treatment in colitis associated cancer
   J. Gonzalez Menezes, T. Marini-Menezes, R. Lakra, S. Wirtz, M.F. Neurath, M.J. Waldner (Erlangen, DE)

60. Nitrates pollution as a possible risk factor for digestive cancer
   D. Neagoe, I. Prejbeanu, C. Deliu, G. Ianosi, A. Farmazon, A. Fetoiu, T. Ciurea (Craiova, RO)
61. Prevalence of Barrett’s esophagus in obese with GERD
D. Neagoe, G. Ianosi, A.-M. Genunche-Dumitrescu, A. Fetoiu, C. Deliu, A. Amzolini, T. Ciurea (Craiova, RO)

62. The reliability of celiac disease serology to reflect intestinal damage
S. Neidhöfer, T. Matthias, P. Jeremias, A. Lerner (Wendelsheim, DE; Haifa, IL)

63. Non-alcoholic steatohepatitis in elderly patients
O.B. Népesova, Y.N. Niýazmuradova, K.B. Népesova (Ashgabat, TM)

64. Hirschsprung’s disease mimicking ileocolonic Crohn’s disease: A case report
O. Ozutemiz, N.G. Unal, M. Sezak, F. Gunsar (Izmir, TR)

65. Eosinophilic oesophagitis: Presentation, diagnosis and response to therapy in a tertiary referral centre in London
I. Parisi, C. Bailey, H. Saravanapavanan, R. Sweis (London, GB)

66. Efficacy of faecal diversion in managing refractory perianal or colonic Crohn’s disease

67. Is there a relationship between gluten ingestion and postural tachycardia syndrome?
H.A. Penny, M. Ferrar, J. Atkinson, N. Hoggard, M. Hadjivassiliou, J.N. West, D.S. Sanders (Sheffield, GB)

68. Analysis of several candidate genes role in acute pancreatitis

69. Kefir supplement and chronic constipation
I. Popa, M.A. Badea, O. Gavrilescu, M. Dranga, A.-M. Chiosa, A. Didita, C. Mihai, C. Cijevschi Prelipcean (Iasi, RO)

70. Effect of a high-fat diet in gallstones formation process
R. del Pozo, M. Munoz, L. Mardones, K. Munoz, S. Roa, F. Rozas, V. Ormazabal (Concepción, CL)

71. Treatment of induced colitis in mice by the Ras antagonist farnesylthiosalicylic acid (FTS)
S. Reif, T. Oron, D. Rachmilewitz, R. Hakla, G.Y. Kloog (Jerusalem, Tel-Aviv, IL)

72. Elevated MMP-3 levels in early RA patients after Borrelia infection
S. Reuter, P. Jeremias, P. Trinder, A. Schwarting, T. Matthias (Wendelsheim, Mainz, DE)

73. Effects of calcium pyruvate in the DCA experimental model of irritable bowel syndrome
74. Intestinal anti-inflammatory effects of goat whey in the DNBS model of mouse colitis

75. Intestinal anti-inflammatory activity of probiotics in DNBS-colitis: Impact of role micro-RNA expression and gut microbiota

76. Impact of Nlrp3 x gut microbiota interactions on experimental colitis and insulin sensitivity
F. Rost, P. Pavlov, S. Wueest, K. Atrott, G. Rogler, D. Konrad, I. Frey-Wagner (Zurich, CH)

77. Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: A case report
J. Rüddel, B.T. Schleenvoigt, E. Schüler, C. Schmidt, M.W. Pletz, A. Stallmach (Jena, Erfurt, DE)

78. Titanium dioxide nanoparticles promote intestinal inflammation through activation of the inflammasome

79. Descriptive analysis of 320 consecutive patients with non-variceal acute upper gastrointestinal bleeding
D.-M. Sahawneh, T. Sahawneh, D. Mihaila, A. Trifan, C. Stanciu, C. Cojocariu (Iasi, RO)

80. Upper gastrointestinal bleeding: Non-variceal vs. variceal haemorrhage
D.-M. Sahawneh, D. Mihaila, S. Bucataru, A. Voinea, A. Trifan, C. Cojocariu (Iasi, RO)

81. Role of SMAD7 in the intestinal epithelium for gut homeostasis
E. Schneider, M.F. Neurath, C. Becker (Erlangen, DE)

82. Endoscopic and morphological characteristics of the upper gastrointestinal tract mucosa in young males with dyspepsia
N. Silivontchik, A. Yanul (Minsk, BY)

83. Assessment of pancreatic exocrine function and fat-soluble vitamins during an episode of acute pancreatitis
S. Siminkovitch, M. Kovacheva-Slavova, B. Vladimirov, J. Genov, R. Mitova, P. Gecov, D. Svinarov, B. Golemanov (Sofia, BG)

84. Treatment optimization of the long-term non-scarring gastroduodenal ulcers
I.M. Skrypnyk, G.S. Maslova, O.F. Gopko (Poltava, UA)

85. Gastric involvement and Helicobacter pylori in Kaposi’s sarcoma
A. Soylu, M. Ozaslan, A.T. Erdemir, B. Karahacioglu, O.A. Aydin, S. Cakmak, F. Guzelbulut, M.S. Gurel (Istanbul, TR)
86. An IBD-associated variant in PTPN22 protects from disease onset in mouse models of colitis
M.R. Spalinger, S.H. Kasper, C. Gottier, S. Lang, G. Rogler, M. Scharl (Zurich, CH)

87. High resolution manometry profile of hiatal hernia in patients before and after fundoplication
I. Stadnicka, E. Klimacka-Nawrot, J. Kurek, K. Bilnik, A. Stadnicki (Sosnowiec, Katowice, Jaworzno, PL)

88. High resolution manometry profile in patients before and after fundoplication
A. Stadnicki, J. Kurek, E. Klimacka-Nawrot, I. Stadnicka, K. Blinik (Sosnowiec, Jaworzno, Katowice, PL)

89. Short-term vitamin D supplementation improves hepatic steatosis as quantified by controlled attenuation parameter (CAP)
C.S. Stokes, I. Papapostoli, F. Lammert (Homburg, DE)

90. Biliary reflux syndrome as a cholecystectomy complication: An underevaluated disease
A.R. Sydorchuk, V.B. Reva, T.V. Reva, O.I. Polyansky, R.I. Sydorchuk (Chernivtsi, UA)

91. “Hepatic view” on acute pancreatitis

92. Molecular-genetic predictor for colonic dysbiosis formation in patients with mesenteric vessels endothelial dysfunction
R.I. Sydorchuk, L.P. Sydorchuk, I.I. Sydorchuk, O.M. Plehutsa, A.R. Sydorchuk (Chernivtsi, UA)

93. The lack of pH-sensing receptor TDAG8 plays a protective role in murine adoptive transfer colitis model

94. Health quality and sexual dysfunction in Turkish IBD patients

95. Lactobacillus bulgaricus GLB44 and Helicobacter pylori infection – A possible eradication: Preliminary clinical results
Y. Valerieva, B. Vladimirov, I. Terziev, L. Boyanova (Sofia, BG)

96. Modification of inflammatory microRNAs in gastric mucosa by aspirin, NSAIDs and proton-pump inhibitors
R. Vasapolli, W. Schirrmeister, M. Venerito, G. Treiber, T. Wex, A. Link, P. Malfertheiner (Magdeburg, DE)

97. Intestinal anti-inflammatory effect of olive leaf extract in the DSS model of mouse colitis
98. A comparison of outcomes of endoscopic retrograde cholangiopancreatography versus percutaneous transhepatic biliary drainage in the management of obstructive jaundice from hepatobiliary tuberculosis: The Philippine General Hospital experience
M.E.J. Villamayor, L.A. Padua, N.S. Bacaltos, V.P. Banez (Manila, PH)

99. Developments of novel diagnostic findings on capsule endoscopy in the small bowel of patients with Crohn’s disease

100. Methotrexate use for maintenance therapy in pediatric Crohn’s disease
K. Weber, M.W. Laass (Dresden, DE)

101. Interferon-λ signalling drives multi-organ disease during bacterial infections
S.J. Wirtz, T. Mchedlidze, M.F. Neurath (Erlangen, DE)

102. Impact of adding antimicrobial agents to endoscopic retrograde cholangiography (ERC) contrast media for prevention of infectious complications in patients with biliary obstruction – A monocenter retrospective study
H. Wobser, A. Gunesch, F. Klebl (Regensburg, DE)

103. Role of cross-sectional imaging modalities in determining therapeutic options for patients with de novo stricturing Crohn’s disease

104. A combination of PillCam®SB2 and SmartPill® in the investigation of patients referred for assessment of known or suspected small-bowel Crohn’s disease and their association with faecal calprotectin levels: Case series
D.E. Yung, J.N. Plevris, A. Koulauouzidis (Kirkcaldy, Edinburgh, GB)

105. Correcting liver function in pancreatic cancer patients with obstructive jaundice
A.A. Yusupbekov (Tashkent, UZ)

106. Fascin-1 as a marker of precursor lesions of pancreatic cancer
J. Zinczuk, A. Pryczynicz, B. Kedra, A. Kemona (Bialystok, PL)
<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
<th>Address/Contact Information</th>
</tr>
</thead>
</table>
| **Prof. Dr. Raja Atreya**     | Medizinische Klinik 1  
Universitätsklinikum Erlangen  
Ulmenweg 18  
91054 Erlangen  
Germany  
raja.atreya@uk-erlangen.de |                                                                                |
| **Prof. Dr. G. E. Boeckxstaens** | Division of Gastroenterology  
Translational Research Center for GI Disorders (TARGID)  
University Hospital Leuven  
KU Leuven  
Herestraat 49  
3000 Leuven  
Belgium  
guy.boeckxstaens@med.kuleuven.be |                                                                                |
| **David A. Brenner, M.D.**    | Professor of Medicine  
UCSD School of Medicine  
UCSD Health Sciences  
1318 Biomedical Sc. Bldg. #0602  
9500 Gilman Drive  
La Jolla CA 92093  
USA  
dbrenner@ucsd.edu |                                                                                |
| **Prof. Dr. Jordi Bruix**     | BCLC Group  
Liver Unit  
Hospital Clinico y Provincial  
Universidad de Barcelona  
c/ Villarroel no. 170  
08036 Barcelona  
Spain  
jbruix@clinic.ub.es |                                                                                |
| **Prof. Dr. Marco J. Bruno**  | Department of Gastroenterology  
Erasmus Medical Center  
’s-Gravendijkwal 230  
3015 CE Rotterdam  
The Netherlands  
m.bruno@erasmusmc.nl |                                                                                |
| **Prof. Dr. Dr. h.c. mult. Markus W. Büchler** | Allgemein-/Viszeralchirurgie  
Universitätsklinikum Heidelberg  
Im Neuenheimer Feld 110  
69120 Heidelberg  
Germany  
markus.buechler@med.uni-heidelberg.de |                                                                                |
| **Michael Camilleri, M.D.**  | Professor of Medicine  
Gastroenterology Research Unit  
Mayo Clinic  
200 First Street SW  
Rochester MN 55905  
USA  
camilleri.michael@mayo.edu |                                                                                |
| **Judy Cho, M.D.**            | Department of Internal Medicine  
Mount Sinai Hospital  
1428 Madison Avenue  
New York, NY 10029  
USA  
judy.cho@mssm.edu |                                                                                |
| **Prof. Dr. Axel Dignass**    | Medizinische Klinik I  
AGAPLESION  
Markus Krankenhaus  
Wilhelm-Epstein-Str. 4  
60431 Frankfurt  
Germany  
axel.dignass@fdk.info |                                                                                |
| **Prof. Dr. Christian Ell**   | Innere Medizin II  
Sana Klinikum Offenbach  
Starkenburgring 66  
63069 Offenbach  
Germany  
christian.ell@sana.de |                                                                                |
Prof. Dr. Emad M. El-Omar
Department of Medicine & Therapeutics
University of Aberdeen
Foresterhill
Aberdeen AB25 2ZD
Scotland
e.el-omar@abdn.ac.uk

J. Gregory Fitz, M.D.
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390-9003
USA
greg.fitz@utsouthwestern.edu

Prof. Dr. Pere Ginès
Unidad de Hepatología
Hospital Clínico y Provincial
Universidad de Barcelona
c/ Villarroel no. 170
08036 Barcelona
Spain
pgines@clinic.ub.es

Prof. Dr. Martin Götz
Innere Medizin 1
Universitätsklinikum Tübingen
Otfried-Müller-Str. 10
72076 Tübingen
martin.goetz@med.uni-tuebingen.de

Prof. Dr. Thomas Gress
Gastroenterologie
Universitätsklinikum Giessen und Marburg
Baldingerstr.
35043 Marburg
Germany
thomas.gress@med.uni-marburg.de

Michael A. Helmrath, M.D.
Director of Surgical Research and Intestinal Rehabilitation
Cincinnati Children’s Hospital Medical Center
3333 Burnet Ave.
Cincinnati, OH 45229-3026
USA
michael.helmrath@cchmc.org

Dr. Tom H. Karlsen
Norwegian PSC research center
Department of Transplantation Medicine
Oslo University Hospital Rikshospitalet
0027 Oslo
Norway
tomhk@ulrik.uio.no

Prof. Dr. Markus M. Lerch
Innere Medizin A
Universitätsklinikum Greifswald
Ferdinand-Sauerbruch-Straße
17489 Greifswald
Germany
lerch@uni-greifswald.de

Prof. Dr. Yulan Liu
Department of Gastroenterology
People’s Hospital of Peking University
11, Southern Street, Xizhimen
100044 Beijing
P. R. China
liuyulan@pkuph.edu.cn

Prof. Dr. Drs. h.c. Peter Malfertheiner
Gastroenterologie/Hepatologie
Universitätsklinikum
Otto-von-Guericke-Universität
Leipziger Str. 44
39120 Magdeburg
Germany
peter.malfertheiner@med.ovgu.de

Prof. Dr. Michael P. Manns
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Germany
manns.michael@mh-hannover.de
Prof. Dr. Tamara Matysiak-Budnik
Hépato-Gastroentérologie & Oncologie Digestive
Institut des Maladies de l’Appareil Digestif
Hôtel Dieu, CHU de Nantes
1 Place Alexis Ricordeau
44093 Nantes Cedex 1
France
tamara.matysiakbudnik@chu-nantes.fr

Prof. Dr. Francis Mégraud
INSERM U853 Laboratoire de Bacteriologie - C.H.U. Pellegrin
Place Amelie Raba-Leon
33076 Bordeaux cedex
France
francis.megraud@chu-bordeaux.fr

Prof. Dr. Ulf Müller-Ladner
Rheumatologie
Kerkhoff-Klinik
Benekestr. 2-8
61231 Bad Nauheim
Germany
u.mueller-ladner@kerkhoff-klinik.de

Richard Peek, M.D.
Vanderbilt Univ Med Ctr Gastro
2215B Garland Ave Suite 1030C
Nashville, TN 37232
USA
richard.peek@vanderbilt.edu

Daniel K. Podolsky, M.D.
Professor of Medicine
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390-9046
USA
daniel.podolsky@utsouthwestern.edu

Dr. Roos E. Pouw
Department of Gastroenterology and Hepatology
Academic Medical Center
Amsterdam
The Netherlands
r.e.pouw@amc.uva.nl

Prof. Dr. Dr. Gerhard Rogler
Klinik für Gastroenterologie and Hepatologie
Universitätsspital Zürich
Rämistrasse 100
8091 Zürich
Switzerland
gerhard.rogler@usz.ch

Prof. Dr. Wolff Schmiegel
Medizinische Universitätsklinik
Ruhr-Universität Bochum
In der Schornau 23-25
44892 Bochum
Germany
wolff.schmiegel@ruhr-uni-bochum.de

Prof. Dr. Jürgen Schölmerich
Universitätsklinikum Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt
Germany
aed@kgu.de

Dr. Alain Schoepfer
Dept. of Gastroenterology
Universitätsklinik Lausanne
CHUV
1011 Lausanne
Switzerland
alain.schoepfer@chuv.ch

Rhonda F. Souza, M.D.
Professor of Medicine
University of Texas Southwestern Medical Center and the
VA North Texas Health Care System-Dallas
Esophageal Diseases Center
Dallas VA Medical Center, MC#111B1
4500 S. Lancaster Road
Dallas, TX 75216
USA
rhonda.souza@utsouthwestern.edu

Prof. Dr. Kentaro Sugano
Division of Gastroenterology
Jichi Medical University
3311-1 Yakushiji, Shimotsuke
Tochigi 329-0498
Japan
sugano@jichi.ac.jp
Prof. Dr. Jan Tack  
Department of Clinical and Experimental Medicine  
Translational Research Center for Gastrointestinal Disorders  
University of Leuven  
Herestraat 49  
3000 Leuven  
Belgium  
jan.tack@med.kuleuven.be

Prof. Dr. Michael Trauner  
Klinische Abteilung für Gastroenterologie & Hepatologie  
Medizinische Universität Wien  
Währinger Gürtel 18-20  
1090 Wien  
Austria  
michael.trauner@meduniwien.ac.at

Prof. Dr. Christian Trautwein  
Medizinische Klinik III  
Universitätsklinikum Aachen  
Pauwelsstr. 30  
52074 Aachen  
Germany  
ctrautwein@ukaachen.de

Prof. Dr. Jan Wehkamp  
Innere Medizin I  
Universitätsklinikum Tübingen  
Otfried-Müller-Straße 10  
72076 Tübingen  
Germany  
jan.wehkamp@med.uni-tuebingen.de

Dr. George Webster  
Consultant Gastroenterologist and Hepatologist  
Clinical Lead for HPB Medicine  
University College London Hospitals  
250 Euston Road  
London NW1 2PG  
george.webster@uclh.nhs.uk

Ramnik J. Xavier, M.D.  
GI Unit  
School of Medicine  
Massachusetts General Hospital  
55 Fruit Street  
Boston MA 02114-2696  
USA  
xavier@molbio.mgh.harvard.edu

Prof. Dr. Stefan Zeuzem  
Innere Medizin I  
Universitätsklinikum Frankfurt  
Theodor-Stern-Kai 7  
60590 Frankfurt  
Germany  
zeuzem@em.uni-frankfurt.de
General Information

Prior to the opening of the congress
Falk Foundation e. V.            Telephone: +49 (0)761/1514-125
Congress Department           Telefax: +49 (0)761/1514-359
Leinenweberstr. 5              E-Mail: symposia@falkfoundation.de
79108 Freiburg (Germany)

Congress Office

During Falk Symposium 200
Konzerthaus Freiburg           Telephone: +49 (0)175/7795327
Konrad-Adenauer-Platz 1
79098 Freiburg
Germany

Opening Hours:
Thursday, October 15, 2015      8.30 – 18.00 h
Friday, October 16, 2015        7.30 – 14.00 h
Saturday, October 17, 2015      8.00 – 17.30 h

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

Congress Report

The official congress report of the Falk Symposium 200 “Therapeutic Strategies in Diseases of the Digestive Tract – 2015 and Beyond” will be published in English in the first half of 2016 by Karger, Switzerland. Orders for this book at a reduced subscription price of € 35.00 can be placed at the Congress Office during the congress in Freiburg.

Congress Short Report

The congress short report of the Falk Symposia 199-200 will be published by the Falk Foundation e.V. with number FSR 199-200 in the first half of 2016.
Airports

EuroAirport Basel-Mulhouse-Freiburg

Frankfurt International Airport
www.frankfurt-airport.com

Airport Transfer
http://www.freiburger-airportservice.de/en/

Train Connections
http://www.bahn.com

Directions to Konzerthaus Freiburg

From the North or the South, take A5 autobahn/motorway Frankfurt-Basel along the Rhine Valley, exit “Freiburg Mitte”. Stay on the autobahn feeder road “Mitte” until exit “Konzerthaus Freiburg” (10 min.), follow signs to the Konzerthaus Freiburg.

A81 Stuttgart-Singen autobahn/motorway or B31 (Höllental), Donaueschingen, Titisee-Neustadt. Go through Freiburg on the Schwarzwaldstrasse, this becomes Schreiberstrasse, direction of the autobahn feeder road “Mitte”. There are road signs to the Konzerthaus Freiburg.

Connections to the French and Swiss autobahn/motorway networks. 950 parking places in the underground car park at the Konzerthaus and central train station (Hauptbahnhof).
Directions to the Konzerthaus Freiburg
Falk Symposium 200

Therapeutic Strategies in Diseases of the Digestive Tract – 2015 and Beyond

October 16 – 17, 2015
Konzerthaus Freiburg
Freiburg, Germany

Program